Compare Torrent Pharma with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs FULFORD INDIA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA FULFORD INDIA TORRENT PHARMA/
FULFORD INDIA
 
P/E (TTM) x 56.9 398.8 14.3% View Chart
P/BV x 6.8 6.2 109.7% View Chart
Dividend Yield % 0.8 0.1 888.2%  

Financials

 TORRENT PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
FULFORD INDIA
Mar-14
TORRENT PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs1,550942 164.5%   
Low Rs1,144450 254.1%   
Sales per share (Unadj.) Rs354.7691.4 51.3%  
Earnings per share (Unadj.) Rs40.111.5 349.6%  
Cash flow per share (Unadj.) Rs64.215.4 418.1%  
Dividends per share (Unadj.) Rs14.002.00 700.0%  
Dividend yield (eoy) %1.00.3 361.8%  
Book value per share (Unadj.) Rs273.1380.0 71.9%  
Shares outstanding (eoy) m169.223.90 4,339.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.81.0 377.2%   
Avg P/E ratio x33.660.7 55.3%  
P/CF ratio (eoy) x21.045.3 46.3%  
Price / Book Value ratio x4.91.8 269.2%  
Dividend payout %34.917.4 200.2%   
Avg Mkt Cap Rs m227,8972,714 8,395.9%   
No. of employees `00014.70.4 3,310.8%   
Total wages/salary Rs m11,353505 2,248.0%   
Avg. sales/employee Rs Th4,083.06,073.0 67.2%   
Avg. wages/employee Rs Th772.31,137.4 67.9%   
Avg. net profit/employee Rs Th461.3100.7 458.2%   
INCOME DATA
Net Sales Rs m60,0212,696 2,226.0%  
Other income Rs m2,988125 2,383.1%   
Total revenues Rs m63,0092,822 2,232.9%   
Gross profit Rs m13,493-46 -29,078.7%  
Depreciation Rs m4,08615 26,881.6%   
Interest Rs m3,08510 32,471.6%   
Profit before tax Rs m9,31054 17,145.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,52910 26,340.6%   
Profit after tax Rs m6,78145 15,170.9%  
Gross profit margin %22.5-1.7 -1,306.3%  
Effective tax rate %27.217.7 153.6%   
Net profit margin %11.31.7 681.5%  
BALANCE SHEET DATA
Current assets Rs m52,6231,738 3,027.3%   
Current liabilities Rs m52,022545 9,550.5%   
Net working cap to sales %1.044.3 2.3%  
Current ratio x1.03.2 31.7%  
Inventory Days Days12048 246.7%  
Debtors Days Days764 1,770.8%  
Net fixed assets Rs m85,01612 714,421.8%   
Share capital Rs m84639 2,169.7%   
"Free" reserves Rs m45,3761,443 3,144.5%   
Net worth Rs m46,2221,482 3,118.9%   
Long term debt Rs m41,1150-   
Total assets Rs m142,4322,077 6,858.6%  
Interest coverage x4.06.7 59.8%   
Debt to equity ratio x0.90-  
Sales to assets ratio x0.41.3 32.5%   
Return on assets %6.92.6 265.4%  
Return on equity %14.73.0 486.4%  
Return on capital %14.24.3 329.7%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m14,58017 84,768.0%   
Fx outflow Rs m3,600673 534.8%   
Net fx Rs m10,980-656 -1,673.9%   
CASH FLOW
From Operations Rs m8,94290 9,935.3%  
From Investments Rs m-47,070105 -44,999.5%  
From Financial Activity Rs m34,174-14 -242,368.1%  
Net Cashflow Rs m-3,655181 -2,024.9%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.0 3.8 184.7%  
FIIs % 12.6 0.1 12,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 21.2 41.5%  
Shareholders   26,511 4,783 554.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   ALEMBIC PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON   

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 172 Points Higher; IT and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours and ended their session near day's high.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Use My Secret to Increase Your Trading Profits Today

Dec 10, 2019

What to do after every trade.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020(Profit Hunter)

Dec 5, 2019

This corner of the market could provide more returns than blue chips in 2020.

What Is the IPO Euphoria Signaling Us About the Markets?(The 5 Minute Wrapup)

Dec 2, 2019

2019 will be remembered as the year of great money-making IPOs...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Dec 11, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS